| 1 |
NCT02470481 |
Completed |
A Study in Participants With Psoriatic Arthritis Attending Dermatology Clinics |
|
|
Observational |
|
- Janssen Research & Development, LLC
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Percentage of Participants With Psoriatic Arthritis
|
250 |
All |
18 Years to 65 Years (Adult) |
NCT02470481 |
CR103908
CNTO148PSA4001 |
PARIS |
March 2015 |
July 2016 |
July 2016 |
June 12, 2015 |
September 2, 2016 |
|
- Fitzroy, Australia
- New Lambton, Australia
- Beijing, China
- (and 2 more...)
|
| 2 |
NCT02814175 |
Recruiting |
A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation |
|
- Drug: methotrexate (MTX)
- Biological: adalimumab
|
Interventional |
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The proportion of subjects achieving minimal disease activity
- Change in DLQI score from baseline
- Change in tender dactylitic digit count from baseline
- (and 10 more...)
|
240 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT02814175 |
M14-496
2016-000191-21 |
CONTROL |
August 5, 2016 |
October 15, 2018 |
August 5, 2019 |
June 27, 2016 |
February 7, 2018 |
|
- AZ Arthritis & Rheum Research
Glendale, Arizona, United States - LeJenue Research Associates
Miami, Florida, United States - Deerbrook Medical Associates
Vernon Hills, Illinois, United States - (and 54 more...)
|
| 3 |
NCT02414633 |
Completed |
Special Investigation in Patients With Psoriatic Arthritis (PsA) (Working Productivity and Activity Impairment (WPAI)) |
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Change in Work Productivity and Activity Impairment (WPAI)
- Change in absenteeism
- Change in Psoriatic Arthritis Screening and Evaluation (PASE) questionnaire
- (and 12 more...)
|
150 |
All |
16 Years to 99 Years (Child, Adult, Senior) |
NCT02414633 |
P15-084 |
|
April 1, 2015 |
March 13, 2017 |
March 13, 2017 |
April 13, 2015 |
May 16, 2017 |
|
- Nagoya City University Hospital /ID# 144958
Aichi, Nagoya, Japan - Akita University Hospital /ID# 140644
Akita, Japan - Anan Kyoei Hospital /ID# 152209
Anan, Japan - (and 82 more...)
|
| 4 |
NCT03486457 |
Not yet recruiting
New |
Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis |
|
- Drug: Tofacitinib
- Other: Placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of Participants With an American College of Rheumatology 50% (ACR50) Response
- Number of Participants Achieving American College of Rheumatology 20% (ACR20) Response
- Number of Participants Achieving American College of Rheumatology 70% (ACR70) Response
- (and 8 more...)
|
153 |
All |
18 Years and older (Adult, Senior) |
NCT03486457 |
A3921234 |
|
August 16, 2018 |
May 7, 2020 |
May 7, 2020 |
April 3, 2018 |
April 3, 2018 |
|
|
| 5 |
NCT02141763 |
Completed |
Multiple Dose Study of UCB4940 in Subjects With Psoriatic Arthritis |
|
- Drug: UCB4940 40 mg
- Drug: UCB4940 80 mg
- Drug: UCB4940 160 mg
- (and 4 more...)
|
Interventional |
Phase 1 |
- UCB Celltech
- Parexel
- MAC Clinical Research, United Kingdom
- (and 3 more...)
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Maximum plasma concentration at steady state (CmaxSS) of UCB 4940 during the duration of the study (up to Day 141)
- Minimum plasma concentration at steady state (CminSS) of UCB4940 during the duration of the study (up to Day 141)
- Area under the curve at steady state (AUCtau) of UCB4940 during the duration of the study (up to Day 141)
- (and 4 more...)
|
53 |
All |
18 Years and older (Adult, Senior) |
NCT02141763 |
PA0007
2013-004949-16 |
|
May 2014 |
August 2015 |
August 2015 |
May 19, 2014 |
September 1, 2015 |
|
- 001
Sofia, Bulgaria - 002
St. Chisinau, Moldova, Republic of - 003
Manchester, United Kingdom
|
| 6 |
NCT02404350 |
Active, not recruiting |
Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis |
|
|
Interventional |
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- American College of Rheumatology 20 (ACR20) response at Week 16
- Van der Heijde modified total Sharp score at Week 24. The method includes, in each hand and foot, evaluations of areas for erosions and areas for joint space narrowing
- Psoriasis Area and Severity Index 75 (PASI75) response at Week 16
- (and 6 more...)
|
998 |
All |
18 Years and older (Adult, Senior) |
NCT02404350 |
CAIN457F2342 |
FUTURE5 |
August 31, 2015 |
August 16, 2017 |
January 16, 2019 |
March 31, 2015 |
February 1, 2018 |
|
- Novartis Investigative Site
Upland, California, United States - Novartis Investigative Site
Aurora, Colorado, United States - Novartis Investigative Site
Denver, Colorado, United States - (and 168 more...)
|
| 7 |
NCT01892436 |
Active, not recruiting |
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis |
|
|
Interventional |
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- ACR 20, 50 , 70
- Change from baseline in Health Assessment Questionnaire Disability Index (HAQ-DI)
- Minimal Clinically Important Difference (MCID) in Health Assessment Questionnaire Disability Index (HAQ-DI)
- (and 3 more...)
|
461 |
All |
18 Years and older (Adult, Senior) |
NCT01892436 |
CAIN457F2306E1
2013-001241-13 |
FUTURE 1 ext |
September 30, 2013 |
November 20, 2017 |
November 20, 2017 |
July 4, 2013 |
February 27, 2017 |
|
- Novartis Investigative Site
Anniston, Alabama, United States - Novartis Investigative Site
Mesa, Arizona, United States - Novartis Investigative Site
Paradise Valley, Arizona, United States - (and 91 more...)
|
| 8 |
NCT01925768 |
Completed
Has Results |
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis |
|
- Drug: Apremilast 30 mg
- Drug: Placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16
- Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) at Week 24
- Percentage of Participants Who Achieve an ACR 20 Response at Week 24
- (and 18 more...)
|
219 |
All |
18 Years and older (Adult, Senior) |
NCT01925768 |
CC-10004-PSA-006 |
|
September 4, 2013 |
February 25, 2015 |
November 17, 2016 |
August 20, 2013 |
April 6, 2017 |
June 13, 2016 |
- Achieve Clinical Research LLC
Birmingham, Alabama, United States - Desert Medical Advances
Palm Desert, California, United States - Bay Area Arthritis and Osteoporosis
Brandon, Florida, United States - (and 68 more...)
|
| 9 |
NCT02065713 |
Completed |
Efficacy of Golimumab in Combination With Methotrexate (Mtx) Versus Mtx Monotherapy, in Improving Dactylitis, in Mtx naïve Psoriatic Arthritis Patients |
|
- Drug: Golimumab
- Drug: Methotrexate
- Drug: Placebo
|
Interventional |
Phase 3 |
- Instituto de Medicina Molecular
- Merck Sharp & Dohme Corp.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Dactylitis Severity Score (DSS)
|
136 |
All |
18 Years and older (Adult, Senior) |
NCT02065713 |
IMM-50307 |
GO-DACT |
August 2014 |
June 2017 |
June 2017 |
February 19, 2014 |
March 8, 2018 |
|
- Centro Académico de Medicina de Lisboa
Lisbon, Portugal
|
| 10 |
NCT03347110 |
Recruiting |
A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis |
|
|
Interventional |
Phase 2 |
- UCB Biopharma S.P.R.L.
- UCB Pharma
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of Adverse Event (AE) during the study
- Incidence of Serious Adverse Event (SAE) during the study
- Subjects who withdrew due to an Adverse Event (AE) during the study
- (and 14 more...)
|
200 |
All |
18 Years and older (Adult, Senior) |
NCT03347110 |
PA0009
2017-001003-74 |
|
November 22, 2017 |
February 2021 |
February 2021 |
November 20, 2017 |
April 13, 2018 |
|
- Pa0009 025
Lexington, Kentucky, United States - Pa0009 003
Hagerstown, Maryland, United States - Pa0009 011
Lansing, Michigan, United States - (and 29 more...)
|
| 11 |
NCT01559038 |
Active, not recruiting |
Canadian Humira Post Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis |
|
|
Observational |
|
- AbbVie (prior sponsor, Abbott)
- Cato Research
- JSS Medical Research Inc.
- AbbVie
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Change in the Disease Activity Score - 28 (DAS-28)
- Duration of Morning Stiffness (min)
- Dermatology Life Quality Index (DLQI)
- (and 3 more...)
|
482 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT01559038 |
P12-666 |
Complete-PsA |
February 16, 2012 |
November 30, 2019 |
November 30, 2019 |
March 21, 2012 |
February 9, 2018 |
|
- Kirk Barber Research, CA
Calgary, Alberta, Canada - Pont, Cranbrook, BC, CA
Cranbrook, British Columbia, Canada - Hudson, Kamloops, Canada
Kamloops, British Columbia, Canada - (and 44 more...)
|
| 12 |
NCT01752634 |
Active, not recruiting |
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis |
|
- Drug: Secukinumab (AIN457)
- Drug: Placebo
|
Interventional |
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Proportion of subjects achieving American College of Rheumatology 20 (ACR20) response criteria
- Proportion of subjects achieving a PASI75 response in the subgroup of subjects who have ≥3% skin involvement with psoriasis
- Proportion of subjects achieving a PASI90 response in the subgroup of subjects who have ≥3% skin involvement with psoriasis
- (and 6 more...)
|
399 |
All |
18 Years and older (Adult, Senior) |
NCT01752634 |
CAIN457F2312
2012-004439-22 |
FUTURE 2 |
April 14, 2013 |
January 18, 2019 |
January 18, 2019 |
December 19, 2012 |
March 2, 2018 |
|
- Novartis Investigative Site
Peoria, Arizona, United States - Novartis Investigative Site
Aventura, Florida, United States - Novartis Investigative Site
Palm Harbor, Florida, United States - (and 73 more...)
|
| 13 |
NCT02188654 |
Completed |
Metformin in Psoriatic Arthritis |
|
- Drug: Metformin
- Drug: Placebo
|
Interventional |
Not Applicable |
- Faculty of Medicine, University of Alexandria
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- ACR20 response
- PASI score
- Health Assessment Questionnaire
- (and 2 more...)
|
56 |
All |
18 Years and older (Adult, Senior) |
NCT02188654 |
alexmed12671416 |
|
September 2013 |
March 2014 |
April 2014 |
July 11, 2014 |
July 11, 2014 |
|
- University of Alexandria
Alexandria, Egypt
|
| 14 |
NCT02598739 |
Completed |
Evaluation of the Effectiveness of Resistance Training in Patients With Psoriatic Arthritis |
|
- Other: Resistance exercise
- Other: Waiting list for the exercises
|
Interventional |
Not Applicable |
- Federal University of São Paulo
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Supportive Care
|
- Change in the functional capacity
- Change in the quality of life
|
41 |
All |
18 Years to 65 Years (Adult) |
NCT02598739 |
0196/11 |
PSA |
May 2014 |
September 2014 |
December 2014 |
November 6, 2015 |
November 6, 2015 |
|
- São Paulo Hospital
São Paulo, Brazil
|
| 15 |
NCT02969525 |
Active, not recruiting |
A Multicenter Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis. |
|
- Other: Placebo
- Drug: Bimekizumab
|
Interventional |
Phase 2 |
- UCB Biopharma S.P.R.L.
- UCB Pharma
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- ACR50 (American College of Rheumatology 50% Improvement) Response at Week 12
- ACR20 (American College of Rheumatology 20% Improvement) Response at Week 12
- ACR70 (American College of Rheumatology 70% Improvement) Response at Week 12
- (and 2 more...)
|
206 |
All |
18 Years and older (Adult, Senior) |
NCT02969525 |
PA0008
2016-001103-23 |
|
October 2016 |
November 2017 |
November 2018 |
November 21, 2016 |
February 16, 2018 |
|
- Pa0008 007
San Diego, California, United States - Pa0008 005
Aventura, Florida, United States - Pa0008 011
Lansing, Minnesota, United States - (and 37 more...)
|
| 16 |
NCT02627768 |
Recruiting |
A Study on Assessment of STELARA and Tumor Necrosis Factor Alpha Inhibitor Therapies in Participants With Psoriatic Arthritis |
|
|
Observational |
|
- Janssen Pharmaceutica N.V., Belgium
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Time to Drug Stop or Switch
- Change From Baseline in Disease Activity Score in 28 Joints (DAS28) at Month 36
- Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) Scores at Month 36
- (and 20 more...)
|
1400 |
All |
18 Years and older (Adult, Senior) |
NCT02627768 |
CR106450
CNTO1275PSA4003 |
PsaBio |
December 17, 2015 |
December 1, 2020 |
June 30, 2021 |
December 11, 2015 |
November 29, 2017 |
|
- CHU Saint Pierre BXL
Brussels, Belgium - Rhumarc Sprl
Ceroux-Mousty, Belgium - Hôpiteux Iris Sud - Molière Longchamp
Forest, Belgium - (and 112 more...)
|
| 17 |
NCT02024646 |
Completed |
Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis |
|
- Drug: 210 mg brodalumab
- Drug: 140 mg brodalumab
- Drug: Placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- American College of Rheumatology (ACR) 20 Response
- Psoriasis Area and Severity Index (PASI) 75
- Health Assessment Questionnaire-Disability Index (HAQ-DI)
- Psoriasis Symptom Inventory responder definition
|
484 |
All |
18 Years and older (Adult, Senior) |
NCT02024646 |
20110144
2013-003553-16 |
AMVISION-2 |
March 2014 |
October 2015 |
October 2015 |
December 31, 2013 |
June 10, 2016 |
|
- Research Site
Peoria, Arizona, United States - Research Site
Little Rock, Arkansas, United States - Research Site
Cypress, California, United States - (and 100 more...)
|
| 18 |
NCT00884468 |
Completed |
Study Evaluating Anxiety and Depression in Patients With Psoriatic Arthritis |
|
|
Observational |
|
- Wyeth is now a wholly owned subsidiary of Pfizer
|
Industry |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Prevalence of anxiety and/or depression disorders in patients suffering from PsA in Spain as measured by the Hospital Anxiety and Depression Scale (HAD)
- To assess the relation between the PsA severity and the presence of anxiety and/or depression disorders in patients suffering from PsA in Spain.
|
384 |
All |
18 Years and older (Adult, Senior) |
NCT00884468 |
0881A5-4468 |
|
May 2008 |
December 2008 |
December 2008 |
April 20, 2009 |
May 27, 2009 |
|
|
| 19 |
NCT00451243 |
Completed |
Differential Clinical and Serologic Response in Psoriasis and Psoriatic Arthritis to Drug Treatment |
|
|
Observational |
|
- National Taiwan University Hospital
|
Other |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
- Time Perspective: Retrospective/Prospective
|
|
20 |
All |
Child, Adult, Senior |
NCT00451243 |
9361701244 |
|
January 2005 |
|
June 2005 |
March 23, 2007 |
March 23, 2007 |
|
|
| 20 |
NCT02029495 |
Terminated
Has Results |
Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis |
|
- Drug: 210 mg brodalumab
- Drug: 140 mg brodalumab
- Drug: Placebo
|
Interventional |
Phase 3 |
- Valeant Pharmaceuticals International, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- American College of Rheumatology (ACR) 20 Response
- Psoriasis Area and Severity Index (PASI)75
|
478 |
All |
18 Years and older (Adult, Senior) |
NCT02029495 |
20090406
2013-003554-25 |
AMVISION-1 |
March 2014 |
October 2015 |
October 2015 |
January 8, 2014 |
May 19, 2017 |
May 19, 2017 |
- Research Site
Huntsville, Alabama, United States - Research Site
Tuscaloosa, Alabama, United States - Research Site
Peoria, Arizona, United States - (and 149 more...)
|
| 21 |
NCT01939132 |
Unknown † |
Protocol for H.P. Acthar Gel in Moderately to Severely Active Psoriatic Arthritis |
|
- Drug: Open label H.P. Acthar Gel
|
Interventional |
Phase 4 |
- Fiechtner, Justus J., M.D., P.C.
- Mallinckrodt
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- ACR20 (American College of Rheumatology 20)
- Adverse Events
|
10 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT01939132 |
02131985 |
|
July 2013 |
July 2014 |
November 2014 |
September 11, 2013 |
September 11, 2013 |
|
- Justus J. Fiechtner, MD, PC
Lansing, Michigan, United States
|
| 22 |
NCT03378336 |
Recruiting |
Psoriatic Arthritis Research Collaborative: Biologic Sub-Study |
|
|
Observational |
|
- University of Pennsylvania
- The Cleveland Clinic
- New York University School of Medicine
- University of Utah
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Patient Function Response to Biologic Therapy as measured by RAPID3
- Patient Function Response to Biologic Therapy as measured by HAQ-DI
- Patient Quality of Life Response to Biologic Therapy as measured by PROMIS10
- (and 6 more...)
|
220 |
All |
18 Years to 89 Years (Adult, Senior) |
NCT03378336 |
828357 |
PARC-B |
December 31, 2017 |
January 1, 2020 |
January 1, 2020 |
December 19, 2017 |
January 31, 2018 |
|
- NYU School of Medicine
New York, New York, United States - Cleveland Clinic
Cleveland, Ohio, United States - Hospital at the University of Pennsylvania
Philadelphia, Pennsylvania, United States - University of Utah
Salt Lake City, Utah, United States
|
| 23 |
NCT01106079 |
Completed |
TIght COntrol of Psoriatic Arthritis |
|
- Drug: Intensive management or Tight control
- Drug: Standard management - Control group
|
Interventional |
Phase 3 |
- Julia Brown
- Arthritis Research UK
- Pfizer
- University of Leeds
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of patients achieving an ACR20 response.
- Additional clinical efficacy outcomes
- Comparison between intensive management and standard care in terms of Quality of Life (QoL),using PsAQoL
- (and 3 more...)
|
206 |
All |
18 Years and older (Adult, Senior) |
NCT01106079 |
RR07/8350
2007-004757-28
18825 |
TICOPA |
May 2008 |
July 2012 |
January 2013 |
April 19, 2010 |
May 28, 2015 |
|
- Chapel Allerton Hospital
Leeds, West Yorkshire, United Kingdom - St Luke's Hospital
Bradford, United Kingdom - York District Hospital
York, United Kingdom
|
| 24 |
NCT02319759 |
Completed |
Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA) |
|
- Drug: Guselkumab
- Drug: Ustekinumab
- Drug: Placebo
|
Interventional |
Phase 2 |
- Janssen Research & Development, LLC
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Percentage of Participants who Achieve an American College of Rheumatology (ACR) 20 Response at Week 24
- Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ-DI) Score at Week 24
- Percentage of Participants who Achieve an American College of Rheumatology (ACR) 20 Response at Week 16
- (and 4 more...)
|
149 |
All |
18 Years and older (Adult, Senior) |
NCT02319759 |
CR105964
2014-003697-17
CNTO1959PSA2001 |
|
March 27, 2015 |
May 31, 2016 |
January 17, 2017 |
December 18, 2014 |
April 10, 2017 |
|
- Huntsville, Alabama, United States
- Trumbull, Connecticut, United States
- Clearwater, Florida, United States
- (and 38 more...)
|
| 25 |
NCT02745080 |
Recruiting |
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis |
|
- Biological: Secukinumab
- Biological: Adalimumab
|
Interventional |
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- American College of Rheumatology 20 (ACR20) response
- PASI90
- ACR50 response
- (and 2 more...)
|
850 |
All |
18 Years and older (Adult, Senior) |
NCT02745080 |
CAIN457F2366 |
EXCEED 1 |
April 3, 2017 |
March 12, 2020 |
March 12, 2020 |
April 20, 2016 |
November 17, 2017 |
|
- Novartis Investigative Site
Kogarah, New South Wales, Australia - Novartis Investigative Site
Maroochydore, Queensland, Australia - Novartis Investigative Site
Hobart, Tasmania, Australia - (and 110 more...)
|
| 26 |
NCT02995460 |
Completed |
Interval Training Study in Psoriatic Arthritis |
|
- Behavioral: interval training
|
Interventional |
Not Applicable |
- Norwegian University of Science and Technology
- Helse Midt-Norge
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Patient global assesment (PGA)
- Maximal oxygen uptake (VO2 max)
- Total lean mass
- Total body fat
|
67 |
All |
18 Years to 65 Years (Adult) |
NCT02995460 |
2012/1646 |
|
January 2013 |
December 2015 |
December 2015 |
December 16, 2016 |
December 19, 2016 |
|
|
| 27 |
NCT01877668 |
Completed
Has Results |
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study |
|
- Drug: Tofacitinib 5 mg BID
- Drug: Tofacitinib 10 mg BID
- Drug: Adalimumab
- Drug: Placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥20% (ACR20): Month 3
- Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score
- Change From Baseline in the Van Der Heijdel Modified Total Sharp Score (mTSS) for Psoriatic Arthritis
- (and 36 more...)
|
422 |
All |
18 Years and older (Adult, Senior) |
NCT01877668 |
A3921091
2011-003668-55 |
OPAL BROADEN |
January 20, 2014 |
December 18, 2015 |
December 18, 2015 |
June 14, 2013 |
July 6, 2017 |
July 6, 2017 |
- Rheumatology Associates, PC
Birmingham, Alabama, United States - Rheumatology Associates of North Alabama, PC
Huntsville, Alabama, United States - Arizona Arthritis & Rheumatology Associates, P.C.
Glendale, Arizona, United States - (and 120 more...)
|
| 28 |
NCT02188641 |
Completed |
Effect of Exercise and Diet on Psoriatic Arthritis |
|
- Other: Diet
- Other: Exercise
- Other: Diet and Exercise
- Other: Healthy Lifestyle (Control) Group
|
Interventional |
Not Applicable |
- Faculty of Medicine, University of Alexandria
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- ACR20 response
- PASI score
- DAS28-CRP response
- (and 2 more...)
|
55 |
All |
18 Years and older (Adult, Senior) |
NCT02188641 |
alexmed12671300 |
|
June 2013 |
July 2014 |
July 2014 |
July 11, 2014 |
July 11, 2014 |
|
- University of Alexandria
Alexandria, Egypt
|
| 29 |
NCT01169844 |
Completed |
Safety and Tolerability of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis |
|
|
Interventional |
Phase 2 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety and tolerability (Vital signs, ECG, Hematology; Blood chemistry; Urinalysis, Adverse Events, Immunogenicity)
- Immunogenicity of AIN457 as measured by anti-AIN457 antibody in serum
- Total IL-17 concentration in blood at steady-state
- Pharmacokinetics of AIN457 at steady state as measured by AIN457 concentration in serum by a competitive ELISA assay.
|
28 |
All |
18 Years to 65 Years (Adult) |
NCT01169844 |
CAIN457A2206E1 |
|
June 2010 |
November 2012 |
November 2012 |
July 26, 2010 |
November 18, 2016 |
|
- Novartis Investigative Site
Berlin, Germany - Novartis Investigative Site
Hamburg, Germany - Novartis Investigative Site
Hamburg, Germany - (and 7 more...)
|
| 30 |
NCT01111240 |
Completed
Has Results |
Efficacy and Safety of Humira® in Patients With Psoriatic Arthritis in Normal Medical Practice |
|
|
Observational |
|
- AbbVie (prior sponsor, Abbott)
- AbbVie
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Mean Change From Baseline in Disease Activity Score (DAS)28
- Mean Tender Joint Count (TJC) Over Time
- Mean Swollen Joint Count (SJC) Over Time
- (and 16 more...)
|
4635 |
All |
18 Years and older (Adult, Senior) |
NCT01111240 |
HUM 05-3 |
|
August 2005 |
December 2013 |
December 2013 |
April 27, 2010 |
December 30, 2014 |
December 30, 2014 |
- Site Reference ID/Investigator# 35035
Aachen, Germany - Site Reference ID/Investigator# 64288
Aachen, Germany - Site Reference ID/Investigator# 35509
Ahlen, Germany - (and 506 more...)
|
| 31 |
NCT03419650 |
Not yet recruiting |
Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS) |
|
|
Interventional |
Phase 4 |
- IRIS Research and Development, LLC
- Mallinckrodt
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Primary Clinical Endpoint
- Primary Imaging Endpoints
- Secondary Imaging Endpoints
|
10 |
All |
18 Years and older (Adult, Senior) |
NCT03419650 |
AC0014 |
CLIPS |
March 26, 2018 |
December 31, 2019 |
December 31, 2019 |
February 2, 2018 |
March 6, 2018 |
|
|
| 32 |
NCT02376790 |
Active, not recruiting |
Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis |
|
- Drug: Etanercept + Oral Methotrexate
- Drug: Etanercept + Placebo for Methotrexate
- Drug: Oral Methotrexate + Placebo for Etanercept
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Efficacy as measured by American College of Rheumatology (ACR) 20 response.
- Minimal Disease Activity (MDA) response of arthritis activity.
- Minimal Disease Activity (MDA) response for measures of non-arthritic PSA disease activity.
- Minimal Disease Activity (MDA) response of patient reported outcomes.
|
851 |
All |
18 Years and older (Adult, Senior) |
NCT02376790 |
20130207 |
|
March 3, 2015 |
January 9, 2018 |
July 6, 2018 |
March 3, 2015 |
April 20, 2018 |
|
- Research Site
Tuscaloosa, Alabama, United States - Research Site
Glendale, Arizona, United States - Research Site
Mesa, Arizona, United States - (and 135 more...)
|
| 33 |
NCT00809614 |
Completed
Has Results |
Efficacy of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis |
|
- Biological: AIN457
- Biological: Placebo
|
Interventional |
Phase 2 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Percentage of ACR Responders Per Treatment at Week 6
- Percentage of PsARC Responders Per Treatment at Week 6
- Percentage of Participants Who Achieved 20%, 50% or 70% Improvement as Measured by ACR Response Criteria
- (and 12 more...)
|
42 |
All |
18 Years to 65 Years (Adult) |
NCT00809614 |
CAIN457A2206 |
|
March 2009 |
December 2010 |
December 2010 |
December 17, 2008 |
November 13, 2015 |
November 13, 2015 |
- Novartis Investigative Site
Berlin, Germany - Novartis Investigative Site
Hamburg, Germany - Novartis Investigative Site
Hamburg, Germany - (and 7 more...)
|
| 34 |
NCT01882439 |
Completed
Has Results |
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors |
|
- Drug: Tofacitinib
- Other: Placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percentage of Participants Meeting American College of Rheumatology Response Criteria Greater Than or Equal to (≥) 20% (ACR20): Month 3
- Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score: Month 3
- Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, and 6
- (and 35 more...)
|
395 |
All |
18 Years and older (Adult, Senior) |
NCT01882439 |
A3921125
2013-001368-46 |
OPAL BEYOND |
August 2013 |
April 2016 |
April 2016 |
June 20, 2013 |
September 15, 2017 |
September 15, 2017 |
- Rheumatology Associates P.C.
Birmingham, Alabama, United States - Rheumatology Associates of North Alabama, PC
Huntsville, Alabama, United States - Arizona Arthritis & Rheumatology Associates, P.C.
Glendale, Arizona, United States - (and 122 more...)
|
| 35 |
NCT00235885 |
Completed |
Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA) |
|
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety parameters
- PsARC
- ACR20
- (and 3 more...)
|
445 |
All |
18 Years and older (Adult, Senior) |
NCT00235885 |
M04-724
EudraCT: 2005/001185-14 |
STEREO |
July 2005 |
|
|
October 12, 2005 |
August 29, 2007 |
|
- Global Medical Information - Abbott
Abbott Park, Illinois, United States
|
| 36 |
NCT03320876 |
Active, not recruiting |
An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis. |
|
|
Interventional |
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in the proportion of subjects with adverse events.
- Proportion of subjects achieving minimal disease activity (MDA).
- Proportion of subjects achieving ACR20 response.
- (and 24 more...)
|
122 |
All |
18 Years and older (Adult, Senior) |
NCT03320876 |
GLPG0634-CL-225
2017-000545-52 |
|
July 26, 2017 |
February 2021 |
February 2021 |
October 25, 2017 |
April 11, 2018 |
|
- ULB Hopital Erasme, Service de Rheumatology
Brussels, Belgium - UMHAT "Kaspela", EOOD
Plovdiv, Bulgaria - MHAT - Ruse, AD
Ruse, Bulgaria - (and 22 more...)
|
| 37 |
NCT01392326 |
Completed
Has Results |
Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) |
|
- Drug: Secukinumab (75 mg)
- Drug: Secukinumab (150 mg)
- Drug: Placebo Comparator
|
Interventional |
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percent of Patients Achieving ACR20 Response Criteria on Secukinumab 75 or 150 mg vs. Placebo
- Percent of Subjects Achieving a PASI75 Response in the Subgroup of Subjects Who Have ≥3% Skin Involvement With Psoriasis at Baseline
- Percent of Subjects Achieving a PASI90 Response in the Subgroup of Subjects Who Have ≥3% Skin Involvement With Psoriasis at Baseline
- (and 7 more...)
|
606 |
All |
18 Years and older (Adult, Senior) |
NCT01392326 |
CAIN457F2306
2011-000276-34 |
FUTURE 1 |
September 2011 |
October 2014 |
October 2014 |
July 12, 2011 |
February 4, 2016 |
February 4, 2016 |
- Novartis Investigative Site
Anniston, Alabama, United States - Novartis Investigative Site
Mesa, Arizona, United States - Novartis Investigative Site
Paradise Valley, Arizona, United States - (and 106 more...)
|
| 38 |
NCT00659412 |
Completed |
A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis |
|
- Drug: Alefacept
- Drug: Methotrexate
- Drug: Placebo
|
Interventional |
Phase 2 |
- Astellas Pharma Inc
- Biogen
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Proportion of patients achieving a score in the assessment system of the American College of Rheumatology Core Set Measurements of ACR 20, ACR 50 and ACR 70
- Proportion of patients achieving a score in the Psoriasis Area and Severity Index of PASI 75, PASI 50 and PASI 25
- Proportion of patients achieving a classification in the Physician's Global Assessment (PGA) of clear/almost clear
- Sharp -VanDen Heijde Modified Score of Joint Damage (X-ray)
|
185 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT00659412 |
C-737 |
|
September 2003 |
March 2005 |
March 2005 |
April 16, 2008 |
September 18, 2014 |
|
- Birmingham, Alabama, United States
- Wheaton, Maryland, United States
- Lake Success, New York, United States
- (and 24 more...)
|
| 39 |
NCT02841176 |
Recruiting |
Thermography in Assessing Treatment Response to Golimumab in Psoriatic Arthritis |
|
- Other: Thermography
- Biological: Golimumab
|
Interventional |
Not Applicable |
- Imperial College Healthcare NHS Trust
- Merck Sharp & Dohme Ltd
- Imperial College London
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
|
- Temperature over arthritic joint surface, measured by thermography
- Psoriatic Arthritis Response Criteria (PsARC)
- Health Assessment Questionnaire (HAQ-DI)
- (and 3 more...)
|
10 |
All |
18 Years to 95 Years (Adult, Senior) |
NCT02841176 |
16HH3180 |
Go-Thermal |
July 2016 |
June 2017 |
June 2017 |
July 22, 2016 |
August 31, 2016 |
|
- NIHR/Wellcome Trust Imperial Clinical Research Facility, Hammersmith Hospital
London, United Kingdom
|
| 40 |
NCT03119805 |
Recruiting |
Remission and Flare in Psoriatic Arthritis: a Prospective 6-month Study With a Double Perspective. |
|
|
Observational |
|
- Groupe Hospitalier Pitie-Salpetriere
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- To determine the cutoff value of PsAID corresponding to flare
- To determine the cutoff value of PsAID corresponding to remission
|
450 |
All |
18 Years and older (Adult, Senior) |
NCT03119805 |
ongoing |
ReFlaP |
May 18, 2017 |
July 2018 |
July 2018 |
April 19, 2017 |
February 20, 2018 |
|
- Ana- Maria Orbai
Baltimore, Maryland, United States - Husni
Cleveland, Ohio, United States - Smolen
Vienna, Austria - (and 19 more...)
|
| 41 |
NCT01516957 |
Terminated |
AMG 827 in Subjects With Psoriatic Arthritis |
|
- Drug: AMG 827
- Drug: Placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- To evaluate the efficacy of AMG 827 in psoriatic arthritis as measured by the proportion of subjects achieving an American College of Rheumatology (ACR) 20% response at week 12
- To evaluate the efficacy of AMG 827 in psoriatic arthritis as measured by the proportion of subjects achieving an ACR 50 response at week 12
- To evaluate the efficacy of AMG 827 in psoriatic arthritis as measured by the proportion of subjects achieving an ACR 70 response at Week 12
- (and 4 more...)
|
168 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT01516957 |
20101227 |
|
October 2011 |
September 2012 |
September 2015 |
January 25, 2012 |
April 13, 2016 |
|
- Research Site
Peoria, Arizona, United States - Research Site
Scottsdale, Arizona, United States - Research Site
Tucson, Arizona, United States - (and 28 more...)
|
| 42 |
NCT03058900 |
Recruiting |
Efficacy and Safety of Fecal Microbiota Transplantation in Peripheral Psoriatic Arthritis |
|
- Drug: Fecal microbiota transplantation (FMT)
- Other: Drug: Placebo (saline)
- Drug: Methotrexate (MTX)
|
Interventional |
Not Applicable |
- Odense University Hospital
- Region of Southern Denmark
- University of Southern Denmark
- (and 3 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Treatment failure
- The Short Health Assessment Questionnaire (2-page HAQ)
- The Dermatology Life Quality Index (DLQI) Questionnaire
- (and 9 more...)
|
80 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT03058900 |
OUH-DC-FLORA-01 |
FLORA |
May 16, 2017 |
July 1, 2019 |
July 1, 2019 |
February 23, 2017 |
May 18, 2017 |
|
- Dept. of Rheumatology at Odense University Hospital
Odense, Denmark - Diagnostic Centre at Silkeborg Regional Hospital
Silkeborg, Denmark
|
| 43 |
NCT03101670 |
Active, not recruiting |
A Study to Assess Efficacy and Safety of Filgotinib in Active Psoriatic Arthritis |
|
- Drug: filgotinib
- Drug: Placebo Oral Tablet
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percentage of subjects who have reached ACR20 response as compared to placebo
- Assessment of minimal disease activity (MDA) in filgotinib treated subjects as compared to placebo
- Percentage of subjects who have reached ACR50 response as compared to placebo
- (and 30 more...)
|
131 |
All |
18 Years and older (Adult, Senior) |
NCT03101670 |
GLPG0634-CL-224 |
EQUATOR |
March 9, 2017 |
June 2018 |
June 2018 |
April 5, 2017 |
March 12, 2018 |
|
- ULB Hopital Erasme, Service de Rheumatology
Brussels, Belgium - UMHAT "Kaspela", EOOD
Plovdiv, Bulgaria - MHAT - Ruse, AD
Ruse, Bulgaria - (and 22 more...)
|
| 44 |
NCT00963313 |
Completed |
A 24 Week Open Label Study of the Utility of Adalimumab in Active Axial Forms of Psoriatic Arthritis |
|
- Drug: Adalimumab (HUMIRA®)
|
Observational |
|
- Dr. FRANCISCO J. BLANCO-GARCIA
- Instituto de Investigacion Biomedica de A Coruna
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- BASDAI score (Bath Ankylosing Spondylitis Disease Activity Index).
- Number of participants with new adverse events.
- ASAS 40 score.
- (and 12 more...)
|
29 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT00963313 |
SUE-ADA-2009-01 |
|
March 2010 |
June 2012 |
June 2014 |
August 21, 2009 |
September 23, 2014 |
|
- Hospital Arquitecto Marcide-Novoa Santos
Ferrol, A Coruna, Spain - Hospital de Elche
Elche, Alicante, Spain - Hospital Comarcal Villajoyosa
Villajoyosa, Alicante, Spain - (and 19 more...)
|
| 45 |
NCT02854163 |
Recruiting |
Effect of Secukinumab in the Treatment of Psoriatic Arthritis |
|
|
Interventional |
Phase 2 |
- University of Liverpool
- Novartis
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Change from baseline in neutrophil apoptosis in PsA patients treated with Secukinumab at 12 months
- Change from baseline in neutrophil receptor expression in PsA patients treated with Secukinumab at 12 months
- Change from baseline in neutrophil rate of phagocytosis in PsA patients treated with Secukinumab at 12 months
- (and 11 more...)
|
20 |
All |
18 Years and older (Adult, Senior) |
NCT02854163 |
UoL001145
2015-004502-42
LCTU134
CAIN457F2208T |
SATURN |
October 2016 |
August 2018 |
August 2018 |
August 3, 2016 |
May 24, 2017 |
|
- Aintree University Hospitals NHS Foundation Trust
Liverpool, United Kingdom
|
| 46 |
NCT03151551 |
Recruiting |
A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis |
|
- Drug: Ixekizumab
- Drug: Adalimumab
|
Interventional |
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Proportion of Participants Simultaneously Achieving American College of Rheumatology (ACR)50 and Psoriasis Area and Severity Index (PASI)100
- Proportion of Participants Achieving ACR50
- Proportion of Participants Achieving PASI100
- (and 25 more...)
|
550 |
All |
18 Years and older (Adult, Senior) |
NCT03151551 |
16687
I1F-MC-RHCF
2016-004585-25 |
SPIRIT-H2H |
August 24, 2017 |
November 1, 2018 |
May 17, 2019 |
May 12, 2017 |
April 19, 2018 |
|
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Buenos Aires, Argentina - For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
Ciudad Autonoma de Buenos Aire, Argentina - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Ciudad Autonoma de Buenos Aire, Argentina - (and 141 more...)
|
| 47 |
NCT01989468 |
Active, not recruiting |
24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis |
|
- Biological: Secukinumab
- Biological: Placebo
|
Interventional |
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- American College of Rheumatology 20 (ACR20) response in subjects treated with secukinumab versus placebo
- American College of Rheumatology 50 (ACR50) response in subjects treated with secukinumab versus placebo
- Disease Activity Score for 28 joints (DAS28-CRP) (utilizing hsCRP) relative to baseline, assessed in subjects treated with secukinumab versus placebo
- (and 7 more...)
|
415 |
All |
18 Years and older (Adult, Senior) |
NCT01989468 |
CAIN457F2318
2013-004002-25 |
|
February 23, 2010 |
March 28, 2018 |
March 28, 2018 |
November 21, 2013 |
March 5, 2018 |
|
- Novartis Investigative Site
Aventura, Florida, United States - Novartis Investigative Site
Palm Harbor, Florida, United States - Novartis Investigative Site
Sarasota, Florida, United States - (and 74 more...)
|
| 48 |
NCT02558361 |
Withdrawn |
Treatment With Apremilast in Patients With Psoriatic Arthritis |
|
- Drug: Treatment with Apremilast
|
Interventional |
Phase 4 |
- University of South Florida
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Comparison of the change in the specific 32 gene products as measured by RT-PCR from baseline to Month 3 on synovial, skin samples (Co-primary endpoints) using the sign test.
- Comparison of the change in the RT-PCR gene products from baseline to Month 3 on blood samples (sign test).
|
0 |
All |
18 Years and older (Adult, Senior) |
NCT02558361 |
PRO00023672 |
|
April 2016 |
October 2016 |
October 2016 |
September 24, 2015 |
October 21, 2016 |
|
- Morsani Center for Advanced healthcare
Tampa, Florida, United States
|
| 49 |
NCT02986373 |
Active, not recruiting |
A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study 1311.5 |
|
|
Interventional |
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Adverse Events
- Change from Baseline in Modified Total Sharp Score (mTSS)
- American College of Rheumatology 20 Response (ACR20)
|
145 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT02986373 |
M16-244
2016-003113-94 |
|
December 15, 2016 |
July 8, 2018 |
July 8, 2018 |
December 8, 2016 |
April 18, 2018 |
|
- Inland Rheum Clin Trials Inc.
Upland, California, United States - University of South Florida
Tampa, Florida, United States - Arthritis and Rheumatology
Atlanta, Georgia, United States - (and 34 more...)
|
| 50 |
NCT01654198 |
Active, not recruiting |
PET/CT in Psoriatic Arthritis |
|
- Radiation: FDG-PET/CT scan
|
Observational |
|
- University of Pennsylvania
|
Other |
- Observational Model: Case-Only
- Time Perspective: Cross-Sectional
|
- Primary outcome is inflammation as measured by SUVmax and metabolic volumetric product in the joints and entheses.
- Correlation of local inflammation in joints and enthesis with systemic inflammatory markers including IL6 and high sensitivity CRP.
|
18 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT01654198 |
815253 |
|
July 2012 |
May 2018 |
May 2018 |
July 31, 2012 |
November 14, 2017 |
|
- University of Pennsylvania Division of Rheumatology
Philadelphia, Pennsylvania, United States
|
Create an RSS feed from your search for:
Download the search results for: